XT
ORMP icon

XTX Topco’s Oramed Pharmaceuticals ORMP Stock Holding History

XTX Topco’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.1K Sell
22,688
-15,494
-41% -$52.6K ﹤0.01% 3185
2025
Q4 		$109K Buy
38,182
+14,297
+60% +$36.9K ﹤0.01% 2614
2025
Q3 		$63.1K Buy
+23,885
New +$52.8K ﹤0.01% 2124
2024
Q4 		– Sell
-24,716
Closed -$60.3K – 2757
2024
Q3 		$60.3K Buy
24,716
+9,242
+60% +$22.5K ﹤0.01% 1667
2024
Q2 		$39.8K Buy
+15,474
New +$36.8K ﹤0.01% 1533
2024
Q1 		– Sell
-17,325
Closed -$40K – 2184
2023
Q4 		$40K Buy
+17,325
New +$37K 0.01% 1274
2023
Q2 		– Sell
-151,620
Closed -$331K – 1718
2023
Q1 		$331K Buy
151,620
+94,537
+166% +$300K 0.07% 579
2022
Q4 		$687K Buy
+57,083
New +$444K 0.15% 179
2022
Q3 		– Sell
-18,174
Closed -$83K – 1309
2022
Q2 		$83K Buy
+18,174
New +$97.1K 0.03% 687
2022
Q1 		– Sell
-10,556
Closed -$151K – 887
2021
Q4 		$151K Buy
+10,556
New +$221K 0.09% 409

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

XTX Topco's ORMP Position: Q1 2026 in Review

XTX Topco reduced its Oramed Pharmaceuticals (ORMP) stake by 41% in Q1 2026, selling an estimated $52.6K and leaving 22,688 shares worth $77.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

XTX Topco first reported a position in ORMP in Q4 2021 and has held it in 10 quarters since. The position peaked at $687K in Q4 2022. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • XTX Topco held 22,688 shares of Oramed Pharmaceuticals worth $77.1K as of Q1 2026.
  • XTX Topco sold 15,494 Oramed Pharmaceuticals shares in Q1 2026, an estimated $52.6K.
  • Oramed Pharmaceuticals made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3185 holding.
  • XTX Topco first reported a position in Oramed Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
  • XTX Topco's Oramed Pharmaceuticals position peaked at $687K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.